Live Breaking News & Updates on Vascular Endothelial Growth Factor Agents

Stay updated with breaking news from Vascular endothelial growth factor agents. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

RGX-314 Gene Therapy for nAMD Well-Tolerated in Phase 1/2a Study

A single administration of ABBV-RGX-314 was generally well tolerated, with little to no supplemental anti-VEGF injections required in most patients at two years. ....

United States , Jeffreys Heier , European Medicines Agency , Regenxbio Inc , Drug Administration , Ophthalmic Consultants , Vascular Endothelial Growth Factor Agents , Retinal Disease , From Bench ,